The US Food and Drug Administration, responding to concerns over the lack of specific postmarketing safety reporting requirements for combination products, has issued a much-awaited proposed rule to address the issue1.
In addition to requiring companies to adhere to the general postmarket safety reporting requirements for drugs, devices and biological products, the FDA has identified five other provisions that it wants companies to comply with...
Please login to read the full article.
